What question did this study set out to answer?

To systematically characterize the genomic hallmarks of ribosome biogenesis across cancers and identify potential therapeutic targets using an in silico activity scoring method.

January 22, 2024Briefings in BioinformaticsOpen Access

Genomic hallmarks and therapeutic targets of ribosome biogenesis in cancer

View Full Paper

Ask AI

Bookmark

Authors

YZYue ZangWenzhou Medical University RXRan XiaAnhui University of Traditional Chinese Medicine JYJie YuanVaughn College of Aeronautics and Technology

Discussion

Member takes

Overview

Computational multi-omics analysis reveals elevated ribosome biogenesis activity linked to poor prognosis across human cancers, highlighting novel genomic targets and therapeutic compounds.

Key Points

To systematically characterize the genomic hallmarks of ribosome biogenesis across cancers and identify potential therapeutic targets using an in silico activity scoring method.
Established an in silico scoring approach to quantify ribosome biogenesis activity using individual transcriptome data.
Analyzed bulk RNA-seq data from 14,645 TCGA/GTEx samples and 917,294 single-cell expression profiles across 13 cancer types alongside multi-omics somatic alteration data.
Ribosome biogenesis activity was significantly elevated in malignant cells and associated with worse survival outcomes, with copy number variations identified as the predominant somatic alteration.
Identified 128 potential therapeutic target genes, including EXOSC4, BOP1, RPLP0P6, and UTP23, and predicted 23 associated therapeutic compounds, such as methotrexate and CX-5461.
Ribosome biogenesis activity correlated with TP53 mutation status, with hyperactive biogenesis predicting poor clinical outcomes specifically in lung cancer patients lacking TP53 mutations.

Cite This Study

Zang et al. (2024) studied this question.

synapsesocial.com/papers/69dab2df615cc0c8eaa3ce42 https://doi.org/10.1093/bib/bbae023

View Full Paper

Ask AI

Bookmark

January 22, 2024Briefings in BioinformaticsOpen Access

Genomic hallmarks and therapeutic targets of ribosome biogenesis in cancer

View Full Paper

Ask AI

Bookmark

Authors

YZYue ZangWenzhou Medical University RXRan XiaAnhui University of Traditional Chinese Medicine JYJie YuanVaughn College of Aeronautics and Technology

Discussion

Member takes

Overview

Computational multi-omics analysis reveals elevated ribosome biogenesis activity linked to poor prognosis across human cancers, highlighting novel genomic targets and therapeutic compounds.

Key Points

To systematically characterize the genomic hallmarks of ribosome biogenesis across cancers and identify potential therapeutic targets using an in silico activity scoring method.
Established an in silico scoring approach to quantify ribosome biogenesis activity using individual transcriptome data.
Analyzed bulk RNA-seq data from 14,645 TCGA/GTEx samples and 917,294 single-cell expression profiles across 13 cancer types alongside multi-omics somatic alteration data.
Ribosome biogenesis activity was significantly elevated in malignant cells and associated with worse survival outcomes, with copy number variations identified as the predominant somatic alteration.
Identified 128 potential therapeutic target genes, including EXOSC4, BOP1, RPLP0P6, and UTP23, and predicted 23 associated therapeutic compounds, such as methotrexate and CX-5461.
Ribosome biogenesis activity correlated with TP53 mutation status, with hyperactive biogenesis predicting poor clinical outcomes specifically in lung cancer patients lacking TP53 mutations.

Cite This Study

Zang et al. (2024) studied this question.

synapsesocial.com/papers/69dab2df615cc0c8eaa3ce42 https://doi.org/10.1093/bib/bbae023

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark